LungBlog

Aradigm Corporation (OTCBB:ARDM) (the “Company“) today announced that review of the clinical data by Novo Nordisk a/s (“Novo Nordisk“), with whom the Company had a collaboration for inhaled insulin, revealed no occurrence of primary lung cancer in patients inhaling insulin using the AERx^® insulin Diabetes Management System (iDMS). AERx iDMS uses an aqueous formulation of insulin delivered by a hand-held electronic inhaler. Review of the clinical trial data for AERx iDMS revealed no cases of primary lung cancer either in the 2,307 patients treated with AERx iDMS or in the 1,218 patients treated with comparator treatments.

A team led by Dr. Khosit Pinmai from Thammasat University has investigated the combination effects of P. emblica and T. bellerica extracts with conventional cytotoxic agents against human cancer cells. This study shows a synergistic effect of P. emblica and T. bellerica extracts with doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells.

A newly published study links the sexually transmitted human papillomavirus, or HPV, to lung cancer, adding lungs to the list of organs scientists say are susceptible to cancer as a result of contracting the most common sexually transmitted infection in the United States.

A newly published study links the sexually transmitted human papillomavirus, or HPV, to lung cancer, adding lungs to the list of organs scientists say are susceptible to cancer as a result of contracting the most common sexually transmitted infection in the United States.

A study by professor Li Mao of the Texas M.D. Anderson Cancer Centre Houston has suggested that perhaps one day a test for lung cancer may be as simple as taking a swab of the mouth.

It seems that 90% of the time damage in the mouth’s molecular tissue structure caused by tobacco is similar to damage of the lung tissue. 1,774 samples were taken from 127 smokers for analysis.

Pfizer Oncology yesterday announced the initiation of a Phase III, global, open-label, randomized, first-line clinical trial to determine whether the addition of CP-751,871 in combination with carboplatin and paclitaxel prolongs survival (overall survival) in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology (e.g., squamous, large cell and adenosquamous histologies). 

CP‑751,871 is a selective fully human monoclonal antibody against the insulin‑like growth factor 1 receptor (IGF‑1R) pathway. Through this inhibition, CP-751,871 blocks one of the key signaling pathways in cancer cells that lead to uncontrolled growth and survival of tumor cells.  This is the first Phase III study (1016) to examine the promising mechanism of action of IGF-1R in patients with non-adenocarcinoma NSCLC, an underserved patient population who have not benefited from recent treatment advances.     

 

The multi-year grant will support Dmitrovsky’s ongoing studies of innovative ways to treat and prevent lung cancer, the number one cause of cancer death for men and women in the United States.

“This is really recognition for my team and for Dartmouth,” says Dmitrovsky. “We’ve made tremendous progress while I’ve been working here due to the collaborative efforts of my outstanding colleagues from Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Dartmouth Medical School, and Dartmouth College. Our team is now moving research findings in lung cancer from the laboratory bench into the clinic.”

Surviving cancer is their common bond, and their current work in cancer advocacy and prevention is what keeps them strong.

“We have what is called ‘the obligation of the cured,’” Joy said.

While cancer will always be in the back of their minds, the four made the decision that it would not prevent them from devoting their lives to raising money, promoting cancer prevention, and being actively involved in raising awareness.

Biopharmaceutical company Spectrum Pharmaceuticals, Inc., said this morning that preclinical data on lucanthone suggest the orally administered small molecule inhibitor of DNA repair could potentially be used for the treatment of lung cancer.

Lung cancer patients in their 80s fare just as well following surgery as their younger counterparts, the results of a new study indicate.

A team of US researchers followed the progress of 1,293 patients with lung cancer, 482 of whom underwent surgical treatment.

The study found that while fewer people over the age of 80 tended to have surgery for their cancer, in most cases, they fared as well and sometimes better than their younger counterparts.